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A B S T R A C T
Subanaesthetic ketamine has recently been established as an effective and rapid treatment for major depressive
disorder showing antidepressant effects for up to 1 week on average. The use of repeated ketamine infusions has
been put forward to augment and to prolong the antidepressant response and increase the remission rates. The
underlying neurobiological mechanisms responsible for ketamine's antidepressant effects remain unclear.
Nevertheless, it has been shown, both in dogs and humans, that ketamine can alter neuronal perfusion and
therefore neuronal function in brain regions involved in psychiatric and behavioural disorders. Consequently,
the aim of the current placebo controlled study was to assess the long-term effects on cerebral perfusion of single
and repeated subanaesthetic ketamine infusions in dogs. Twelve healthy, laboratory dogs were scanned at six
different time points following single and repeated ketamine administration, using Single Photon Emission
Computed Tomography with the radiotracer 99mTc-hexamethylpropylene amine oxime. We hypothesised that
repeated infusions could lead to more prolonged perfusion alterations in brain regions critical for behaviour
regulation. We found that repeated subanaesthetic ketamine administration did not result in more prolonged
cerebral perfusion alterations compared to a single ketamine administration.
1. Introduction
Ketamine is a dissociative anaesthetic which is routinely used in veter-
inary and in human medicine, especially in paediatric anaesthesia and field
medicine (Morgan and Curran, 2012). Over the past decade, ketamine has
gained high interest among psychiatrists as an effective treatment for major
depressive disorder (Coyle and Laws, 2015; Dewilde et al., 2015; Fond et al.,
2014; Lee et al., 2015). Subanaesthetic doses, given as a 40-min constant
rate infusion, have been shown to produce rapid-onset antidepressant ef-
fects in patients with severe and treatment-resistant depression. Whereas
traditional antidepressants typically require several weeks to show ther-
apeutic efficacy, ketamine exerts its actions within hours. Moreover, these
effects are sustained beyond ketamine's 3-h half-life, with persistent re-
sponses for up to 1 week on average (Coyle and Laws, 2015; Dewilde et al.,
2015; Lee et al., 2015). Furthermore, the antidepressant response can even
be prolonged when repeated ketamine infusions are given (Murrough et al.,
2013; Rasmussen et al., 2013; Shiroma et al., 2014). The underlying neu-
robiological mechanisms responsible for these antidepressant effect remain
unclear (du Jardin et al., 2016; Mathew et al., 2012), but a possible ex-
planation could be that ketamine interacts with cerebral perfusion. Brain
imaging studies using positron emission tomography (PET), single photon
emission computed tomography (SPECT) and functional magnetic re-
sonance imaging (fMRI) have reported abnormal regional cerebral blood
flow (rCBF) in certain brain regions of dogs (Peremans et al., 2003;
Vermeire et al., 2009) and humans (Deckersbach et al., 2006; Eren et al.,
2003; Etkin and Wager, 2007; Fitzgerald et al., 2008; Järnum et al., 2011;
Rogers et al., 2004) suffering from anxiety and mood disorders. Following
administration of subanaesthetic ketamine doses, altered perfusion in these
brain regions was reported in both humans and dogs (Holcomb et al., 2005,
2001; Pollak et al., 2015; Rowland et al., 2010; Waelbers et al., 2015). All
these studies focused on rCBF evaluation during or immediately following a
single ketamine infusion. However, ketamine's antidepressant effects occur
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later, with a significant clinical improvement 2–4 h after administration
(Abdallah et al., 2015; Carlson et al., 2013; Coyle and Laws, 2015; Singh
et al., 2016). In a previous study by our group, we demonstrated regional
cerebral blood flow changes 24 h after single and repeated ketamine infu-
sions in dogs. This time frame corresponds with peak antidepressant re-
sponses observed in human patients (Abdallah et al., 2015). Nevertheless,
regional brain perfusion 24 h after a single ketamine infusion did not differ
from rCBF measured 24 h after 5 consecutive ketamine infusions in dogs
(Vlerick et al., 2018). In human literature on major depression, it is de-
scribed that repeated ketamine infusions are associated with higher re-
sponse and remission percentages and with a more durable antidepressant
response compared to single infusions (Murrough et al., 2013; Rasmussen
et al., 2013; Shiroma et al., 2014). Therefore, Vlerick et al. hypothesized
that rCBF measured after a single ketamine perfusion would differ from
rCBF measured after repeated infusions. Unfortunately, this hypothesis
could not be confirmed, as indicated above. However, rCBF was only
measured 24 h after single and repeated infusion and therefore prolonged
perfusion alterations following repeated ketamine administration cannot be
excluded.
Consequently, the aim of the current study was to assess the long-term
effects on cerebral perfusion of single and repeated subanaesthetic ketamine
infusions in healthy dogs, measured with SPECT. As opposed to rodents,
dogs have a substantial frontal cortex and exhibit naturally occurring be-
havioural disorders, which makes them an interesting animal model for
human psychiatric diseases (Cyranoski, 2010; DeFelipe, 2011; Overall,
2000; Peremans et al., 2003; Vermeire et al., 2012, 2009). Moreover, due to
their shorter life expectancy, radioprotective regulations are less stringent in
dogs than in humans, which allows repeated SPECT scans in a relatively
short time frame. rCBF was assessed at six different time points following
single and repeated ketamine infusion: at baseline, 4 h, 24 h, 1 week, 1
month and at 3 months post-infusion. We hypothesised that repeated in-
fusions could lead to prolonged perfusion alterations in brain regions critical
for behaviour regulation.
2. Methods
2.1. Animals
Twelve healthy neutered adult laboratory dogs (10 females, 2
males; Beagles; age 3.9 ± 0.2 years; weight 12,7 ± 1.1 kg) were
included in this study. None of the dogs had a history of previous
neurological or behavioural abnormalities. This study was approved by
the local Ethical Committee of the Faculty of Veterinary Medicine,
Ghent University (EC 2016_118) and all manipulations were performed
according to good animal practice. Welfare of the animals was re-
spected at each time and great care was taken to avoid stress and an-
xiety. In this respect, all procedures were conducted under sedation or
general anaesthesia. Sedation or premedication was always performed
under minimal restraint (low stress handling) in the presence of the
principal animal caretaker in a room familiar to the dogs. Following
injection, the animals were allowed to relax in the shelter of a dog
kennel until an appropriate level of sedation was reached. The dogs
were socially-housed in small groups (2–8 dogs) on an internal surface
of 15 m2 with permanent access to an outside area of 15 m2. The
bedding material in the inner part consisted of wood shavings on top of
a bottom heated concrete floor. Feeding toys, such as Kongs® were
provided on a regular basis. Twice a day, the animals were allowed to
run and play outside in an enclosed play area, enriched with climbing
platforms, hiding places and small bushes. In addition, the dogs were
regularly walked by students of the faculty of veterinary medicine.
2.2. Study design
To evaluate the effect of single and repeated subanaesthetic ketamine
administration (Nimatek®, Eurovet Animal Health B.V, Bladel, Nederland)
on rCBF, all dogs underwent SPECT scans at 6 different time points in a
randomized design. SPECT acquisitions were performed before the start of
the ketamine/saline infusions (T1), 4 h (T2), 24 h (T3), 1 week (T4), 1
month (T5) and 3 months (T6) after single or repeated infusions. The ani-
mals were randomly divided into two groups: a group receiving the active
treatment (group A) and a placebo group (group P). Group A consisted of 8
dogs, while the remaining 4 dogs were included in the placebo group. In
group A, each animal first received a single ketamine infusion at a dose of
2 mg/kg, followed by SPECT scans at the time points described above
(condition KET1) (Fig. 1). Once the SPECT scans were completed (after T6),
the animals of group A were re-enrolled in a second part of the study. In this
second part, they received five consecutive subanaesthetic ketamine infu-
sions at 2 mg/kg in a Monday–Wednesday–Friday scheme during a 10-day
period, adapted from human psychiatry (condition KET5) (aan het Rot
et al., 2010; Murrough et al., 2013; Shiroma et al., 2014; Szymkowicz et al.,
2013; Vande Voort et al., 2016). SPECT acquisitions were again performed
at the aforementioned time points (Fig. 1). The animals in group P received
five saline infusions in a Monday–Wednesday–Friday schedule, followed by
SPECT scans at the same time points (condition saline) (Fig. 1). In all dogs,
Fig. 1. Schematic overview of the study design.
Condition KET1 is shown in (A), condition KET5 and
condition saline are demonstrated in (B). The animals
in group A first underwent the infusion/scan protocol
as shown in (A), followed by the infusion/scan pro-
tocol demonstrated in (B). The animals in group P
received 5 saline infusions, as shown in (B).
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the total dose of ketamine or saline was administered intravenously over a
40-min time period. The dosages used are in the order of what it is described
in human psychiatry and are based on the results of a previous study by our
group (Coyle and Laws, 2015; Dewilde et al., 2015; Fond et al., 2014; Lee
et al., 2015; Vlerick et al., 2018). In dogs, the most commonly used an-
aesthesia induction dose of ketamine is 5 mg/kg and 2 mg/kg is considered
to be a subanaesthetic dose (Kästner, 2016).
2.3. Ketamine administration protocol
Prior to each ketamine or saline administration, all dogs were sedated
intramuscular with dexmedetomidine (375 μg/m2 body surface,
Dexdomitor®, Orion Corporation, Espoo, Finland).
Dexmedetomidine–ketamine is a frequently used combination in veterinary
anaesthesia and has been shown to produce fewer sympathomimetic and
haemodynamic side effects than ketamine alone (Murrell, 2016). An in-
travenous 22G over-the-needle catheter (Optiva®, Jelco Smiths Medical In-
ternational Ltd, Rossendale, UK) was placed in one of the cephalic veins and
the animals were allowed to relax in a quiet room until an appropriate level
of sedation was obtained. To evaluate the sedation level, the sedation
scoring system, described by Carter et al. (Carter et al., 2013) was used. The
level of sedation was assessed on a numeric rating scale where 0=no se-
dation; 1= standing or sitting and head lower than before sedation;
2=standing or sitting unbalanced, muscle weakness and refusing to lie
down; 3= lying in sternal recumbency but responsive; 4= lying in lateral
recumbence but responsive; and 5= lying in lateral recumbency and un-
responsive. Infusions were started when a sedation score of 4 or 5 was
reached. A constant rate infusion (CRI) of ketamine or saline was given
intravenously at a rate of 0.0125 ml/kg/min, over a 40-min time period
using a syringe driver (B. BraunMelsungen AG, Perfusor® space, Melsungen,
Germany). During the infusions, the principal investigator monitored the
animals and cardiovascular parameters and sedation scores were evaluated
every 10 min. Following termination of the infusion, the cephalic catheter
was removed and the animals were allowed to recover.
2.4. Anaesthetic protocol
SPECT acquisitions were obtained under general anaesthesia. All dogs
were premedicated with intramuscular dexmedetomidine (375 μg/m2 body
surface) approximately 30 min prior to induction. To gain intravenous ac-
cess, a 22G over-the-needle cephalic catheter was placed in one of the front
legs. General anaesthesia was induced with propofol (Propovet Multidose®,
Abbott Laboratories, Berkshire, United Kingdom) given intravenously to
effect. After endotracheal intubation, anaesthesia was maintained with a
mixture of 1.2%–1.4% isoflurane (Isoflo®, Abbott Laboratories, Berkshire,
UK) vaporized in oxygen using a circle rebreathing system. During general
anaesthesia, heart rate, respiratory rate, end tidal carbon dioxide con-
centration and arterial haemoglobin oxygen saturation were measured by
means of a calibrated multigas analyser (Capnomac Ultima, Datex, Helsinki,
Finland) and a pulse oximeter (N5500 Patient Monitor, Nellcor Puritan
Bennett Inc., Pleasanton, CA, USA).
2.5. SPECT perfusion imaging
99mTc-HMPAO (99mTc-labelled d, 1, hexamethyl propylene amine
oxime, Ceretec, GE healthcare LTD, UK) was synthesised by eluting
99mTcO4 from a 99Mo generator and directly adding it to exametazime.
Finally, the solution was stabilized by adding cobalt. SPECT imaging with
99mTc-HMPAO is a validated technique to study rCBF in dogs (Adriaens
et al., 2013; Peremans et al., 2001). The lipophilic tracer passes the blood
brain barrier and is taken up by neurons, in a manner proportionally to
cerebral blood flow and neuronal function. In the neurons, it is transformed
into a hydrophilic form and becomes trapped intracellular (Adriaens et al.,
2013). Following premedication with dexmedetomidine, a cephalic catheter
was placed and the tracer was administered intravenously (25.7 MBq/
kg ± 5.2 MBq). All SPECT acquisitions were started between 10 min and
20 min after tracer injection. Prior to the acquisition, all dogs were posi-
tioned in ventral recumbence. The triple headed gamma camera (Triad,
Trionix, Twinsburg, OH, USA) was equipped with low-energy ultrahigh
resolution parallel hole collimators (tomographic resolution full width at
half maximum=9 mm). To facilitate comparison between dogs, camera
and table positioning were standardized. Data were acquired over a circular
360-degree rotation, for 20 min in step-and-shoot mode (120 steps, 10 s per
step, 3 degree per step) on a 128× 128matrix. Images were then processed
using iterative reconstruction and a Butterworth filter (cut-off 1.6 cycle/cm,
order 10). Pixel size was 1.72 mm (Vermeire et al., 2009).
2.6. Image analysis
The individual patient's perfusion images were automatically registered
to a template, generated from 14 dogs (9 males, 5 females, mean age 50
months ± 20), using Brain Registration and Automated SPET
Semiquantification software (BRASS, Nuclear diagnostics, Sweden)
(Peremans et al., 2003). This template based automated registration method
eliminates subjective operator dependent region definition and the auto-
matic registration (allowing shifting, scaling and rotation of the data) fa-
cilitates the fitting procedure to the template, necessary to compensate for
intra-individual differences in anatomical brain size and shape. On this
template, a region map was generated, including 12 separate manually
drawn volumes of interest (VOI) positioned over the frontal, temporal,
parietal and occipital lobes of both hemispheres as well as over the cere-
bellum, the thalamic region, the basal ganglia and the bulbus olfactorius. To
calculate the rCBF ratios (perfusion index (PI)), regional radioactivity was
normalized to the radioactivity of the entire brain.
2.7. Statistical analysis
Rstudio 1.1.383 (R: A Language and Environment for Statistical
Computing; R Core Team; R Foundation for Statistical Computing, Vienna,
Austria, 2016, https://www.R-project.org/) with packages MASS (version
7.3-45) and Sommer (version 3.0) was used to compute all analyses.
Onto the data set a multivariate linear mixed model with heterogeneous
(unstructured) variances was set up. The model was written as
E(Yt|T1,T2)=β0+β1t1+β2t2+β3t3+β4t4+β5t5+β6T1+β7T2+
β8t1T1+β9t2T1+β10t3T1+β11t4T1+β12t5T1+β13t1T2+β14t2T2+
β15t3T2+β16t4T2+β17t5T2 with Yt as response variable. The PI of the 12
VOI's (continuous) was set as response value whereas time and treatment
(both categorical) were set as predictor value. The factor time (continuous)
and animal (categorical) were set as random factors. The predictor time (t)
denotes the different timepoints with t1 the first of five
(k−1=6−1=5) dummies (= 1 if time point=“4 h post” or 0
otherwise), t2 the second dummy (= 1 if time point=“24 h post” or 0
otherwise), t3 (= 1 if time point=“1 week post” or 0 otherwise), t4 (=1 if
time point=“1 month post” or 0 otherwise) and t5 (=1 if time point=“3
months post” or 0 otherwise). The treatment predictor (T) indicated the
different treatment modalities with T1 the first of two (k−1=3−1=2)
dummies (= 1 if treatment=“Active 1×” or 0 otherwise) and T2 (= 1 if
treatment=“Active 5×” or 0 otherwise). The reference level (for each
region) was set as the PI at baseline in the control group (intercept). The
degrees of freedom were obtained by means of the Welch-Satterthwaite
equation and the type-I error was set at 0.05 (two-tailed). The assumptions
of linearity of the regression function and the normality of the error term
were assessed by making diagnostics plots.
3. Results
For the single dosage (condition KET1), significant time treatment
interactions were found for the second time point (4 h post-ketamine
infusion) in the following brain regions: left occipital (p-value= 0.04),
right occipital (p-value < 0.001), left parietal (p-value < 0.001) and
right parietal cortex (p-value= 0.001) (Table 1), indicating a sig-
nificant increase in rCBF in these brain regions, compared to the
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reference level. Only for the left occipital and left parietal cortex these
changes remained significant until time point 3 (24 h post-ketamine
infusion) (p-value respectively 0.04 and 0.05). In addition, at this time
point the rCBF of the thalamic region increased significantly (p-
value=0.04) compared to the reference level.
When repeated infusions were given (condition KET5), changes
(compared to the reference level) were only noticeable in the left and
right parietal cortex at time point 2 (4 h post-ketamine infusion) (p-
value respectively 0.01 and 0.04) (Table 1). Again, rCBF increase of the
left parietal cortex was present until time point 3 (24 h post-ketamine
infusion) (p-value=0.04). Once again, also the thalamic region
showed an increased rCBF (p-value=0.04) at time point 3.
4. Discussion
To unravel the underlying neurobiological mechanisms responsible for
ketamine's antidepressant effects, this healthy dog study investigated
changes in rCBF after single (condition KET1) and repeated (condition
KET5) ketamine infusions at six different time points. The main finding of
this study was that, in contrast to our initial hypothesis, repeated sub-
anaesthetic ketamine infusions, administered through a
Monday–Wednesday–Friday scheme, did not provoke more prolonged cer-
ebral perfusion alterations compared to a single ketamine infusion.
However, several studies in human literature have described a progressive
increase in response and remission rate with increasing amount of ketamine
infusions (Murrough et al., 2013; Shiroma et al., 2014; Singh et al., 2016).
Moreover, repeated ketamine infusions prolonged the durability of anti-
depressant response compared with a single infusion, even after the infu-
sions were discontinued (Murrough et al., 2013; Shiroma et al., 2014; Vande
Voort et al., 2016). In one study evaluating antidepressant response to 6
thrice-weekly ketamine infusions, the antidepressant response was still
maintained at the end of the 4-week follow-up period in 45% of responders
after the last infusion (Shiroma et al., 2014). In another study using the
same treatment paradigm, the median time to relapse among responders
was 18 days after the final ketamine infusion (Murrough et al., 2013). The
durability of antidepressant response after a single ketamine infusion is
markedly shorter, with relapse rates ranging between several days to 1 week
(Ibrahim et al., 2012; Zarate et al., 2006). However, in our study, perfusion
alterations after five consecutive ketamine infusions were no longer sig-
nificant 1 week after the last infusion. These results indicate that ketamine's
sustained antidepressant effects after repeated infusions are not associated
with sustained perfusion changes. Nevertheless, to our knowledge there are
no functional imaging studies in human medicine evaluating the long-term
effects of repeated ketamine infusions on rCBF. It could be that the increase
in rCBF is only required as the initial triggering factor for ketamine's long-
term clinical effects. Further downstream neuronal signalling and effects on
neurotransmitters may be involved in the long-term behavioural effects of
ketamine. On the other hand, this study was conducted in healthy dogs with
normal cerebral perfusion. It could be possible that ketamine influences
rCBF in a different way in dogs with abnormal behaviour if they have al-
tered cerebral perfusion compared with behaviourally healthy dogs. To
assess this hypothesis, examination of the long-term effects of single and
repeated ketamine infusions on rCBF in a comparable population of dogs
with anxiety disorders would be needed. The secondary advantage of a
comparison study is that true clinical effects could be assessed, something
neither relevant nor possible here.
In healthy dogs, a single ketamine infusion caused increases in rCBF in
the parietal, occipital and thalamic region. In the thalamic region, the in-
crease in rCBF was evident 24 h after the infusion. This time point corre-
sponds with peak antidepressant effects of ketamine in human patients
(Abdallah et al., 2015). Several human studies also demonstrated increased
rCBF in the thalamic region during or immediately following ketamine in-
fusion (Holcomb et al., 2005, 2001; Rowland et al., 2010). The changes in
rCBF in the parietal and occipital cortices were already detectable 4 h after
ketamine administration. This time frame corresponds with the rapid onset
of antidepressant effects after intravenous ketamine administration
(Abdallah et al., 2015; Carlson et al., 2013; Coyle and Laws, 2015; Singh
et al., 2016). Furthermore, various studies demonstrated increased rCBF or
increased regional glucose metabolic rate in parietal and occipital cortices
during or immediately following subanaesthetic ketamine infusion in
human patients (Carlson et al., 2013; De Simoni et al., 2013; Langsjo et al.,
2004; Vollenweider et al., 1997). In addition, in one healthy dog study,
increased rCBF was found in right parietal cortices during subanaesthetic
ketamine infusion, using a slightly higher dose than in the current study
(Waelbers et al., 2015). Furthermore, various studies in human medicine
have reported decreased parietal and occipital perfusion in patients
Table 1
Perfusion indices (mean± standard deviation) in the thalamic region, parietal, occipital and frontal cortex in three different conditions (condition saline, KET1 and
KET5) and at six different time points (T1–T6), measured using 99mTc-HMPAO SPECT (*≤0.05; †≤0.005).
T1 T2 T3 T4 T5 T6
Saline Th 1.16 ± 0.06 1.17 ± 0.03 1.17 ± 0.06 1.18 ± 0.05 1.16 ± 0.03 1.17 ± 0.04
RP 1.12 ± 0.04 1.10 ± 0.03 1.13 ± 0.03 1.14 ± 0.04 1.14 ± 0.03 1.14 ± 0.05
LP 1.16 ± 0.02 1.14 ± 0.04 1.15 ± 0.03 1.18 ± 0.05 1.18 ± 0.05 1.14 ± 0.05
RO 1.15 ± 0.05 1.17 ± 0.05 1.15 ± 0.02 1.15 ± 0.04 1.20 ± 0.02 1.14 ± 0.06
LO 1.20 ± 0.03 1.20 ± 0.01 1.15 ± 0.03 1.16 ± 0.04 1.20 ± 0.04 1.14 ± 0.04
RF 1.10 ± 0.01 1.12 ± 0.04 1.13 ± 0.02 1.13 ± 0.02 1.10 ± 0.04 1.12 ± 0.04
LF 1.14 ± 0.01 1.14 ± 0.01 1.15 ± 0.04 1.15 ± 0.02 1.12 ± 0.02 1.14 ± 0.04
KET1 Th 1.18 ± 0.05 1.26 ± 0.05 1.28 ± 0.06* 1.26 ± 0.03 1.21 ± 0.06 1.18 ± 0.05
RP 1.13 ± 0.04 1.14 ± 0.05† 1.18 ± 0.03 1.16 ± 0.04 1.12 ± 0.05 1.13 ± 0.04
LP 1.16 ± 0.03 1.19 ± 0.01† 1.22 ± 0.03* 1.20 ± 0.02 1.17 ± 0.05 1.16 ± 0.03
RO 1.11 ± 0.05 1.12 ± 0.04† 1.12 ± 0.06 1.11 ± 0.05 1.10 ± 0.09 1.11 ± 0.05
LO 1.13 ± 0.05 1.14 ± 0.05* 1.14 ± 0.05* 1.13 ± 0.04 1.12 ± 0.07 1.13 ± 0.05
RF 1.10 ± 0.03 1.12 ± 0.03 1.14 ± 0.03 1.15 ± 0.03 1.13 ± 0.04 1.10 ± 0.03
LF 1.15 ± 0.03 1.16 ± 0.03 1.18 ± 0.03 1.19 ± 0.02 1.16 ± 0.04 1.15 ± 0.03
KET5 Th 1.18 ± 0.05 1.26 ± 0.06 1.28 ± 0.06* 1.25 ± 0.07 1.23 ± 0.02 1.23 ± 0.07
RP 1.13 ± 0.04 1.15 ± 0.04* 1.14 ± 0.05 1.16 ± 0.06 1.14 ± 0.05 1.14 ± 0.04
LP 1.16 ± 0.03 1.18 ± 0.03* 1.18 ± 0.03* 1.20 ± 0.06 1.16 ± 0.03 1.16 ± 0.04
RO 1.11 ± 0.05 1.12 ± 0.04 1.12 ± 0.05 1.11 ± 0.07 1.12 ± 0.02 1.12 ± 0.03
LO 1.13 ± 0.05 1.14 ± 0.04 1.14 ± 0.04 1.13 ± 0.06 1.13 ± 0.03 1.13 ± 0.06
RF 1.10 ± 0.03 1.13 ± 0.02 1.13 ± 0.03 1.12 ± 0.03 1.10 ± 0.02 1.12 ± 0.03
LF 1.15 ± 0.03 1.17 ± 0.03 1.17 ± 0.01 1.14 ± 0.03 1.13 ± 0.03 1.14 ± 0.04
Th, thalamic region; RP, right parietal cortex; LP, left parietal cortex; RO, right occipital cortex; LO, left occipital cortex; RF, right frontal cortex; LF, left frontal
cortex. Condition saline, five saline infusions in a Monday–Wednesday–Friday schedule during a 10-day period; condition KET1, a single ketamine infusion at a dose
of 2 mg/kg; condition KET5, five ketamine infusions at 2 mg/kg in a Monday–Wednesday–Friday scheme during a 10-day period. T1, baseline SPECT scan; T2, scan
4-h post-infusion; T3, scan 24-h post-infusion; T4, scan 1-week post-infusion; T5, scan 1-month post-infusion; T6, scan 3-months post-infusion.
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suffering from major depressive disorder (Biver et al., 1994; Bonne et al.,
1996a; Bonte et al., 2001; Drevets, 1998; Ishizaki et al., 2008; Nagafusa
et al., 2012). Moreover, response to antidepressant therapy is generally
associated with normalization of rCBF abnormalities in these brain regions
(Bonne et al., 1996b; Ishizaki et al., 2008; Kohn et al., 2007; Mervaala et al.,
2001).
Twenty-four hours after a single ketamine infusion, perfusion was still
increased in the left parietal and in the left occipital cortex, but not in the
same regions of the right hemisphere. Also 24 h after repeated ketamine
infusions, perfusion was increased in the left parietal but not in the right
parietal cortex. These differences between both hemispheres may be ex-
plained by a relatively small sample size, resulting in limited power.
Nevertheless, there is some scientific evidence that reductions in brain
perfusion in MDD patients are predominantly situated in the left hemisphere
(Nagafusa et al., 2012; Navarro et al., 2002; Rogers et al., 2004).
Perfusion changes in the parietal, occipital and thalamic region can also
be linked to the dissociative state caused by ketamine. Dissociative states in
patients with depersonalization disorder and post-traumatic stress disorder
(PTSD) have been associated with increased activity of the parietal and
occipital cortex (Irle et al., 2007; Lanius et al., 2002; Simeon et al., 2000). In
addition, the thalamus plays an important role in dissociation, and changes
in activity of this brain region have been reported in patients with the
dissociative subtype of PTSD and dissociative identity disorder (Felmingham
et al., 2008; Krause-Utz et al., 2017; Schlumpf et al., 2014). However, dis-
sociative symptoms caused by subanaesthetic ketamine are usually con-
sidered mild and typically resolve within 2–4 h following administration of
ketamine (aan het Rot et al., 2010; Shiroma et al., 2014; Singh et al., 2016;
Vande Voort et al., 2016). The fact that the perfusion of the parietal, occi-
pital and thalamic region was still altered 24 h after ketamine administra-
tion, questions the possibility of a link between these changes and dis-
sociation caused by ketamine.
In line with rCBF abnormalities found in humans suffering from de-
pression and anxiety disorders, also in dogs with pathological anxiety al-
terations in rCBF have been reported (Vermeire et al., 2009). This is an
interesting finding, as it means that ketamine could be a valuable alternative
treatment for dogs with an incomplete response to standard behavioural
therapy and pharmacotherapy or for dogs with the need of a faster response.
Indeed, the management of behavioural disorders is challenging and
treatment outcome is often unsatisfactory (Beata et al., 2007; Landsberg
et al., 2008; Sherman and Mills, 2008; Takeuchi et al., 2000). This results in
rehoming, relinquishment to an animal shelter or even euthanasia of
healthy dogs (Scarlett et al., 2002; Sherman and Mills, 2008). Consequently,
faster and more effective treatments are required.
Since sedation or anaesthesia is required during image acquisition
in veterinary medicine, dogs were under general anaesthesia during
brain imaging. Due to the rapid intra-neuronal trapping mechanism of
the tracer used in this study, the influence of sedation and anaesthesia is
generally considered to be minimal (Adriaens et al., 2014; Waelbers
et al., 2012). Additionally, a placebo group was included to further
eliminate possible confounding effects of sedatives and anaesthetics.
In conclusion, ketamine caused increases in rCBF in the parietal, occi-
pital and thalamic regions, but not in the frontal cortex, in this healthy dog
study. Additionally, repeated subanaesthetic ketamine infusions, adminis-
tered through a Monday–Wednesday–Friday scheme, did not provoke more
prolonged cerebral perfusion alterations compared to a single ketamine
infusion. These results indicate that sustained antidepressant responses fol-
lowing repeated ketamine administration are not associated with sustained
perfusion changes in brain regions critical for behaviour regulation. The
study also emphasizes the advantages of the dog as animal model for human
psychiatric conditions. As radioprotective regulations are less stringent in
dogs, longitudinal studies with repeated SPECT scans in a relatively short
time frame are possible. Since such a study protocol is less feasible in human
patients, studies in dogs can be of great value. Additionally, also dogs with
anxiety disorders could benefit from this study as they show similar changes
in brain activity and perfusion compared to humans with anxiety disorders.
Indeed, treatment of canine anxiety disorders also includes similar first line
psychopharmacological support as in human patients with a similar lag time
before effect. Due to its rapid onset of action, ketamine in subanaesthetic
doses may therefore also be useful as induction therapy in the canine spe-
cies. However, as the study was conducted in healthy dogs, clinical effects of
repeated subanaesthetic ketamine administration could not be assessed.
Therefore, it would be interesting to examine the long-term effects of single
and repeated ketamine infusions on behaviour and on regional cerebral
perfusion in a population of dogs with anxiety disorders with abnormal
cerebral perfusion.
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